Esther Sanfeliu

2.7k total citations · 1 hit paper
24 papers, 338 citations indexed

About

Esther Sanfeliu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Esther Sanfeliu has authored 24 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Esther Sanfeliu's work include Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (10 papers) and Cancer Treatment and Pharmacology (3 papers). Esther Sanfeliu is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (10 papers) and Cancer Treatment and Pharmacology (3 papers). Esther Sanfeliu collaborates with scholars based in Spain, United States and Italy. Esther Sanfeliu's co-authors include María Vidal, Fara Brasó‐Maristany, Tomás Pascual, Montserrat Muñoz-Mateu, Aleix Prat, Patricia Galván, Benedetta Conte, Olga Martínez‐Sáez, Francesco Schettini and Blanca González‐Farré and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Esther Sanfeliu

18 papers receiving 335 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

2020 227 citations Olga Martínez‐Sáez, Núria Chic et al. Breast Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Esther Sanfeliu Spain	5	157	149	131	106	58	24	338
Timothy G. Cleaver United States	7	142 0.9×	240 1.6×	162 1.2×	85 0.8×	47 0.8×	7	415
Kate Moodie Australia	7	108 0.7×	89 0.6×	159 1.2×	55 0.5×	57 1.0×	15	295
Megan Ludwig United States	11	75 0.5×	190 1.3×	104 0.8×	75 0.7×	46 0.8×	31	318
Shiaowen David Hsu United States	10	122 0.8×	102 0.7×	181 1.4×	46 0.4×	69 1.2×	37	313
Mariantonia Nacchio Italy	12	232 1.5×	137 0.9×	183 1.4×	207 2.0×	51 0.9×	31	433
Gwendoline Soler France	11	200 1.3×	170 1.1×	150 1.1×	96 0.9×	50 0.9×	14	415
Judit Matito Spain	9	97 0.6×	218 1.5×	208 1.6×	72 0.7×	22 0.4×	23	365
Kelsey Poorman United States	9	176 1.1×	125 0.8×	292 2.2×	77 0.7×	195 3.4×	27	450
Brigitte Poirot France	9	91 0.6×	171 1.1×	164 1.3×	120 1.1×	30 0.5×	12	375
Cristina Quero Spain	10	73 0.5×	175 1.2×	133 1.0×	86 0.8×	31 0.5×	19	367

Countries citing papers authored by Esther Sanfeliu

Since Specialization

Citations

This map shows the geographic impact of Esther Sanfeliu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther Sanfeliu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther Sanfeliu more than expected).

Fields of papers citing papers by Esther Sanfeliu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther Sanfeliu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther Sanfeliu. The network helps show where Esther Sanfeliu may publish in the future.

Co-authorship network of co-authors of Esther Sanfeliu

This figure shows the co-authorship network connecting the top 25 collaborators of Esther Sanfeliu. A scholar is included among the top collaborators of Esther Sanfeliu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther Sanfeliu. Esther Sanfeliu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Muñoz, Javier, Natalia García, Sergi Ganau, et al.. (2025). Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review. The Breast. 81. 104465–104465.

Sanfeliu, Esther, Elia Seguí, Raquel Gómez Bravo, et al.. (2024). Abstract PO2-01-13: Clinico-Pathological and Molecular Characterization of Early Hormone Receptor-Positive Breast Cancer in Young Women. Cancer Research. 84(9_Supplement). PO2–1. 1 indexed citations

Ganau, Sergi, Sergi Vidal‐Sicart, Francesco Schettini, et al.. (2024). Predicting Additional Metastases in Axillary Lymph Node Dissection After Neoadjuvant Chemotherapy: Ratio of Positive/Total Sentinel Nodes. Cancers. 16(21). 3638–3638.

Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.

Schettini, Francesco, Michela Palleschi, Fara Brasó‐Maristany, et al.. (2024). CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The Oncologist. 29(5). e622–e634. 4 indexed citations

Mensión, Eduard, I. Alonso, Esther Sanfeliu, et al.. (2023). ASO Visual Abstract: Nonsentinel Axillary Lymph-Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph-Node—A Predictive Model Proposal. Annals of Surgical Oncology. 30(9). 5707–5708. 1 indexed citations

Mensión, Eduard, Xavier Caparrós, Sergi Ganau, et al.. (2023). Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram. Cancers. 15(8). 2392–2392. 4 indexed citations

Mensión, Eduard, I. Alonso, Esther Sanfeliu, et al.. (2023). Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal. Annals of Surgical Oncology. 30(8). 4657–4668. 3 indexed citations

Indacochea, Alberto, Marianna Sirico, Esther Sanfeliu, et al.. (2023). Unexpected Durable Complete Response With Anti–PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis. JCO Precision Oncology. 7(7). e2300051–e2300051.

10.

Prat, Aleix, Tomás Pascual, Montserrat Muñoz-Mateu, et al.. (2023). Abstract P3-06-02: TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis. Cancer Research. 83(5_Supplement). P3–6. 4 indexed citations

11.

Carrillo, Pilar, Daniel Santana, María Sepúlveda, et al.. (2022). Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder. SHILAP Revista de lepidopterología. 7(1). 11–16. 3 indexed citations

12.

Schettini, Francesco, Elia Seguí, Benedetta Conte, et al.. (2022). Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. Frontiers in Oncology. 12. 1009352–1009352. 4 indexed citations

13.

Coronado-Gutiérrez, David, Sergi Ganau, Xavier Bargalló, et al.. (2022). Quantitative ultrasound image analysis of axillary lymph nodes to differentiate malignancy from reactive benign changes due to COVID-19 vaccination. European Journal of Radiology. 154. 110438–110438. 4 indexed citations

14.

Brasó‐Maristany, Fara, Miriam Sansó, Núria Chic, et al.. (2021). Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Frontiers in Oncology. 11. 710596–710596. 5 indexed citations

15.

Martínez‐Sáez, Olga, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2020). 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i). Annals of Oncology. 31. S17–S17.

16.

González‐Farré, Blanca, Paolo Nucíforo, Javier Cortés, et al.. (2020). 15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis. Annals of Oncology. 31. S22–S22.

17.

Schettini, Francesco, Núria Chic, Fara Brasó‐Maristany, et al.. (2020). 23P Clinical, pathological and gene expression features of HER2-low breast cancer. Annals of Oncology. 31. S24–S24. 1 indexed citations

18.

Martínez‐Sáez, Olga, Núria Chic, Tomás Pascual, et al.. (2020). Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research. 22(1). 45–45. 227 indexed citations breakdown →

19.

Ballesteros, Esther, et al.. (2012). Calcification in biliary hamartomatosis. British Journal of Radiology. 85(1012). e99–e101. 6 indexed citations

20.

Ramírez‐Lázaro, María José, Sergio Lario, Álex Casalots, et al.. (2011). Real-Time PCR Improves Helicobacter pylori Detection in Patients with Peptic Ulcer Bleeding. PLoS ONE. 6(5). e20009–e20009. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact